[Edaily Reporter Kwon Oh Seok ] NGeneBio Co., Ltd.(354200) The stock price surged to the daily upper limit early in the trading session. It appears that buying interest is surging following news that the company has begun supplying its “HEMEaccuTest,” a precision diagnostic panel for blood cancers, to Seoul National University Bundang Hospital.

According to MP Doctor on the 21st, as of 9:13 a.m., NGeneBio Co., Ltd. is trading at the daily price limit of 1,825 won, up 29.99% from the previous trading day.
Earlier that day, the company issued a press release stating, “This supply demonstrates that NGeneBio Co., Ltd.’s precision diagnostic business for blood cancers is expanding its clinical application scope, centered on major tertiary general hospitals in Korea.” NGeneBio Co., Ltd. plans to continue its growth momentum by aggressively expanding into domestic and international markets based on its full-cycle panel portfolio, which covers everything from the diagnosis of blood cancers to monitoring for recurrence.
NGeneBio Co., Ltd. currently supplies PowerAcuteTest to approximately 20 major tertiary general hospitals in Korea, including Seoul St. Mary’s Hospital and Seoul National University Hospital’s main campus, and this supply to Seoul National University Bundang Hospital further strengthens its domestic clinical references. Overseas, the company is expanding its supply network to countries such as Singapore, Vietnam, Colombia, Germany, and Romania, thereby reinforcing its global presence.
This is also translating into strong financial results. NGeneBio Co., Ltd.’s blood cancer panel business has maintained an average annual growth rate of 36% over the past five years. In the first quarter of this year, revenue grew sharply, rising 38% domestically and 102% internationally compared to the same period last year. In particular, the pace of growth in overseas sales is accelerating, establishing the blood cancer panel business as one of NGeneBio Co., Ltd.’s core growth drivers.
Song Myung-jun, Head of the Diagnostics Business Division at NGeneBio Co., Ltd., stated, “Supplying Seoul National University Bundang Hospital will further enhance the clinical reliability and practical applicability of NGeneBio Co., Ltd.’s blood cancer panel.” He added, “Based on expanded supply to major domestic hospitals and the securing of global references, we will continue to expand our presence in the precision diagnostics market for blood cancers.”